PTK2B
ENSG00000120899
Target class
Kinase
Chromosome
8
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- PTK2B
- Gene name
- Protein tyrosine kinase 2 beta
- Gene symbol
- PTK2B
- Previous gene symbols
- FAK2
- Protein name
- Protein-tyrosine kinase 2-beta (EC 2.7.10.2) (Calcium-dependent tyrosine kinase) (CADTK) (Calcium-regulated non-receptor proline-rich tyrosine kinase) (Cell adhesion kinase beta) (CAK-beta) (CAKB) (Focal adhesion kinase 2) (FADK 2) (Proline-rich tyrosine kinase 2) (Related adhesion focal tyrosine kinase) (RAFTK)
- CAKB
- PYK2
- RAFTK
- PTK
- CADTK
- Gene biotype
- Protein coding
- Gene family
- Minor histocompatibility antigens|FERM domain containing|PTK2 family tyrosine kinases|MicroRNA protein coding host genes
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 233.14
- Tissue specificity (Gini)
- 0.547
- Tissue specificity (tau)
- 0.841
- KEGG gene identifiers
- hsa:2185
- Protein interaction confidence
- 0.883228
- Protein interaction partners
- 57
- R-HSA-391160
- R-HSA-4420097
- R-HSA-9013420
- R-HSA-9020558
- End position
- 27459392
- Start position
- 27311456
- Chromosome
- 8
- Strand
- Forward
- Cytoplasm. Cytoplasm, perinuclear region. Cell membrane
- Peripheral membrane protein
- Cytoplasmic side. Cell junction, focal adhesion. Cell projection, lamellipodium. Cytoplasm, cell cortex. Nucleus. Note=Interaction with NPHP1 induces the membrane-association of the kinase. Colocalizes with integrins at the cell periphery.
- Cytosol
- Plasma membrane
- Tissue specificity (tau)
- 0.840716
- Expression inequality (Gini)
- 0.547228
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 233.14
- Brain - Cerebellar Hemisphere
- 230.8
- Brain - Cerebellum
- 220.79
- Whole Blood
- 119.63
- Brain - Frontal Cortex (BA9)
- 116.58
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes233.14
- Brain - Cerebellar Hemisphere230.8
- Brain - Cerebellum220.79
- Whole Blood119.63
- Brain - Frontal Cortex (BA9)116.58
- Spleen105.96
- Brain - Cortex105.57
- Brain - Nucleus accumbens (basal ganglia)60.35
- Brain - Anterior cingulate cortex (BA24)59.69
- Brain - Hippocampus55.36
- Skin - Not Sun Exposed (Suprapubic)52.44
- Small Intestine - Terminal Ileum49.73
- Lung47
- Skin - Sun Exposed (Lower leg)46.92
- Prostate41.3
- Brain - Amygdala33.44
- Minor Salivary Gland31.8
- Brain - Caudate (basal ganglia)30.25
- Fallopian Tube27.61
- Colon - Transverse26.86
- Nerve - Tibial25.47
- Adipose - Visceral (Omentum)25.37
- Vagina24.24
- Esophagus - Mucosa22.16
- Brain - Putamen (basal ganglia)21.52
And 29 more, listed on the interactive page.
- GO:0001954
- GO:0006915
- GO:0007165
- GO:0007166
- GO:0007229
- GO:0008284
- GO:0008285
- GO:0008360
- GO:0010595
- GO:0010976
- GO:0018108
- GO:0030155
- GO:0030335
- GO:0030838
- GO:0033209
- GO:0038083
- GO:0042976
- GO:0043066
- GO:0043267
- GO:0045638
- GO:0045860
- GO:0046330
- GO:0046777
- GO:0048010
- GO:0048167
And 5 more, listed on the interactive page.
- GO:0005634
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0005925
- GO:0014069
- GO:0030027
- GO:0048471
- GO:0004713
- GO:0004715
- GO:0005515
Related records
Trials (109)
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
- A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects
- A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
- A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
- A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
- A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
- A Study of Avutometinib and Defactinib in People With Thyroid Cancer
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
- A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
- A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
- A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
- A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
- A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
- A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
Drugs (5)
- Conteltinib Protein tyrosine kinase 2 beta inhibitor
- Defactinib Protein tyrosine kinase 2 beta inhibitor
- Defactinib hydrochloride Protein tyrosine kinase 2 beta inhibitor
- Lorlatinib
- PF-00562271